Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end - ...

As one of the leading voices on responsible AI, Gonzalez will join two high profile sessions to discuss the pros and cons of ...

Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.

Q3 2025 Earnings Call Transcript November 6, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the American States Water Company conference call discussing the company’s third ...

New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as develop ...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence ...

AWS noted that the project adds a vital alternative route for transatlantic data traffic, improving network resilience.

RIDE-001 was developed using Trained Therapeutix’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This ...

Good afternoon. Welcome to the Amprius Technologies Third Quarter 2025 Earnings Conference Call. Joining us for today's presentation are the company's CEO, Dr. Kang Sun; President, Tom Stepien; and ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first month The Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, an ...